Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tekmira Pharmaceuticals, a biotechnology company, has reported that Bristol-Myers Squibb Company has exercised an option to extend through 2009 the research collaboration between the two companies.
Subscribe to our email newsletter
The collaboration focuses on validating certain gene targets using small interfering RNA (siRNA) provided by Bristol-Myers Squibb and employing Tekmira’s stable nucleic-acid lipid particle (SNALP) formulations to deliver the siRNA.
Mark Murray, president and CEO of Tekmira, said: “Our continuing relationship with Bristol-Myers Squibb exemplifies our strategy of collaborating with the world’s leading pharmaceutical companies to expand the potential applications of our SNALP technology. These collaborations also complement our internal product development programs as we advance our own RNAi therapeutics to treat serious human diseases.”